NCT05989802Recruiting
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
Rapid Research in Diagnostics Development for Tuberculosis Network (R2D2 Kids) and Assessing Diagnostics At Point-of-care for Tuberculosis in Children (ADAPT for Kids)
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years. The Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and the Assessing Diagnostics at Point-of-care for Tuberculosis in children (ADAPT for Kids) studies seek to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests for use in children.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2100 (estimated)
- First submitted
- 28 Jul 2023
- Start date
- 26 Jan 2024
- Primary completion date
- 1 Sept 2030
- Lead sponsor
- University of California, San Francisco
- Diseases
- Tuberculosis
- NCT number
- NCT05989802
What you commit to
- Study type: Interventional
- Planned participants: 2100
- From 26 Jan 2024 to the primary completion date, 1 Sept 2030
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Participant eligibility criteria:
- Participants will include children (age \<15 years) who present to care with:
- 2 or more of the following:
- Unexplained cough for any duration
- TB contact or tuberculin skin test or interferon gamma release assay positive
- Abnormal chest X-ray (any abnormality) OR
- Any one of criteria A AND any one of the following:
- Unexplained weight loss OR unexplained failure to thrive OR Severe Acute Malnutrition
- Unexplained fever ≥2 weeks
- Unexplained lethargy or reduced playfulness ≥2 weeks
- The study will exclude participants who:
- Completed preventive or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
- Have taken any medication with anti-mycobacterial activity for any reason for greater than 3 days at the time of enrollment (to reduce false-negatives);
- Are unable to return for follow-up visits; or
- Whose parents/guardians are unwilling to provide informed consent or who are unwilling to provide assent if applicable (age determined by local IRB)
- Assessment of the usability of novel TB tests:
- The study will also include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). Personnel who are unwilling to provide informed consent will be excluded.
Age in the registry: - to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Saude Coordinator of this site? Confirm its status | Maputo | Mozambique | Recruiting |
| Mulago National Referral Hospital Coordinator of this site? Confirm its status | Kampala | Uganda | Not yet recruiting |
| Dora Nginza Hospital Coordinator of this site? Confirm its status | Cape Town | South Africa | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.